On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on PRs and Gain Exclusive Benefits with NNW Prime! Click to View Details
ThursdayJan 19, 2017 12:26 pm

NetworkNewsBreaks – Celsius Holdings, Inc. (CELH) Sees Strength in International Presence, Sales

Celsius Holdings (OTCQX: CELH) is science-based beverage company actively expanding its international presence. The company most recently launched its CELSIUS® fitness drink into supermarkets, convenience and specialty stores and fitness centers in Singapore.  News of this expansion followed a record third-quarter performance, marked by sales of $6.7 million, up 82% YoY. While domestic revenue grew 53%, the company saw particular strength in international sales, which increased 147%. Celsius in November also partnered with the A.S. Watson Group (ASW) for distribution of CELSIUS in Hong Kong and Macau, providing a foothold in the growing Chinese energy drink category. To learn more…

Continue Reading

ThursdayJan 19, 2017 11:56 am

NetworkNewsBreaks – CV Sciences, Inc. (CVSI) Mines the Benefits of Science and Nature to Build Cannabidiol-Based Portfolio

The strategic integration of science and nature is the cornerstone of operations at CV Sciences (OTCQB: CVSI). Its Pharmaceuticals Division, for example, is developing synthetically formulated cannabidiol (CBD)‐based medicine for which the company is pursuing FDA approval. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for the treatment of a range of medical conditions. The company’s initial drug candidate (CVSI-007) is a chewing gum containing nicotine and synthetic CBD to support cessation of smokeless tobacco use and addiction. Focusing on enhancing the quality of life, CV Sciences’ Consumer Products Division delivers botanical-based CBD products such…

Continue Reading

ThursdayJan 19, 2017 11:53 am

NetworkNewsBreaks – PURE Bioscience, Inc. (PURE): 2017 Poised to be ‘Breakout Year’

Demonstrating the growing acceptance for its antimicrobial products, PURE Bioscience (OTCQB: PURE) recently posted first-quarter revenues of $531,000, up 186% year-over-year. Core food safety revenues increased 902% year-over-year, an achievement the company attributes to the accelerating momentum of its focused food safety strategy. PURE is pursuing regulatory approval for use of PURE Control in poultry online reprocessing, and said it expects FDA and USDA approvals in the second quarter of 2017. In its earnings release, company CEO Hank Lambert forecasts calendar 2017 as PURE’s “breakout year.” To learn more visit www.purebio.com About PURE Bioscience, Inc. PURE Bioscience, Inc. is focused…

Continue Reading

ThursdayJan 19, 2017 11:51 am

NetworkNewsBreaks – Sphere 3D (NASDAQ: ANY) Inks Deal to Acquire HVE and Unified ConneXions; Shares Higher

Shares of Sphere 3D (NASDAQ: ANY) are up 28% after the data management company said it will acquire HVE (Hybrid Virtualization Engine) ConneXions and its sister company, Unified ConneXions, Inc., which achieved combined virtualization revenue of more than $7 million for calendar year 2016. The acquired companies’ products, technologies and professional services will expand Sphere 3D’s virtualization practice and increase its ability to accelerate the delivery of hybrid cloud solutions. The acquisition is anticipated to close before January 31, 2017, and is expected to be accretive in the first quarter of 2017.  “UCX has exceptional leadership teams, innovative technology, industry…

Continue Reading

ThursdayJan 19, 2017 11:48 am

NetworkNewsBreaks – Rosetta Genomics Ltd. (NASDAQ: ROSG) Sets Stage for Value Creation in 2017

Rosetta Genomics (NASDAQ: ROSG) is an international company leveraging a growing IP portfolio to develop and commercialize microRNA-based and other molecular diagnostic programs in cancer and various other indications. In 2016, Rosetta was primarily focused on the commercial launch of its Reveal assay for the classification of indeterminate thyroid nodules, and it signed an exclusive distribution agreement with Rhenium Ltd. for the sales and marketing of Reveal in Israel. In a December earnings release, Rosetta Genomics said it expects FY2017 RosettaGX Reveal revenue to be between $4 million and $5 million. The company is also advancing a number of other…

Continue Reading

WednesdayJan 18, 2017 2:23 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 18, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: VPRB 18.09% – News: Presenting at 2017 Big Industry Show in Los Angeles on January 19-20th NXTD 16.48% – News:  Posts preliminary results for the year and quarter ended December 31, 2016 UNXL 11.90% – News: Announces preferred equity financing for $3M; Enters into MOU with GIS HPCQ 12.26% – News: Adds Myco BioBoost to product line ESEA 7.83%– News: Announces delivery of Newbuilding Ultramax Drybulk Carrier STLT 7.25% – News: Subsidiary Caretta Therapeutics…

Continue Reading

WednesdayJan 18, 2017 2:19 pm

NetworkNewsBreaks – BiondVax Pharmaceuticals’ (NASDAQ: BVXV) Flu Vaccine Candidate Shows Potential to Cover Mutating Strains

One of the primary concerns of conventional vaccination is historically low efficacy.  BiondVax (NASDAQ: BVXV), which earlier this month received an investment of $2.8 million to continue its development, is focused on creating a universal flu vaccine that would provide effective, multi-season protection. The company’s M-001 vaccine was recently featured in peer-reviewed scientific journal Vaccine, which reports that M-001 administered in the 2011 flu season significantly increased protective antibodies against the strain (A/Swiss) that caused the 2014/2015 influenza epidemic. Notably, the A/Swiss strain did not exist when M-001 was administered several years before. The results demonstrate M-001’s ability to provide…

Continue Reading

WednesdayJan 18, 2017 1:25 pm

NetworkNewsBreaks – aTyr’s (NASDAQ: LIFE) Resolaris™ Obtains Fast Track Designation from FDA, Partial Clinical Hold Removed

Shares of aTyr Pharma (NASDAQ: LIFE) climbed more than 25% in mid-day trade following news that the company’s Resolaris™ candidate was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of limb girdle muscular dystrophy 2B, making it the first known therapeutic candidate to receive the designation for this treatment. The FDA also removed its partial clinical hold on a dosing ceiling for Resolaris in clinical trials, providing dosing flexibility moving forward. "This Fast Track designation, which is granted to drug candidates addressing serious conditions and that demonstrate the potential to address unmet medical…

Continue Reading

WednesdayJan 18, 2017 1:21 pm

NetworkNewsBreaks – Apricus Biosciences (NASDAQ: APRI) Shares Skyrocket on Approval of Vitaros® in Mexico

Shares of Apricus Biosciences (NASDAQ: APRI) soared more than 153% after the company announced that Mexico has granted Apricus’ commercialization partner, Ferring Pharmaceuticals, market approval for Vitaros®, an on-demand topical cream for erectile dysfunction. Per an agreement between the two companies, Apricus has received a total of $4.5 million in upfront payments from Ferring, in addition to a regulatory milestone payment of $1.6 million. Apricus is eligible to receive up to an additional $28 million in regulatory, launch and sales milestones, plus royalties on future net sales. Ferring is anticipated to launch in Mexico and Argentina during the second quarter…

Continue Reading

WednesdayJan 18, 2017 10:45 am

NetworkNewsBreaks – Aegis Reiterates ‘Buy’ Rating for Xtant Medical Holdings, Inc. (NYSE: XTNT) following 2016 Preliminary Results, Guidance for 2017

Noting two quarters of double-digit growth, Aegis Capital has reiterated its 'Buy' rating and $3.50 price target for Xtant Medical (NYSE MKT: XTNT). Xtant Friday reported preliminary fourth quarter 2016 revenues of at least $24.5 million, an increase of 10% compared to the year ago quarter, and in line with Aegis estimates of $24.6 million. Adjusted EBITDA for the fourth quarter is expected to be at least $1.25 million vs a loss of $350,000 in the fourth quarter of 2015, shy of Aegis’ estimates of $1.5 million. Xtant estimates full-year 2016 revenue of at least $90 million, up 4.1% compared…

Continue Reading

Contact us: 212.418.1217